​
​

Cabaletta Bio (CABA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CABA Stock Forecast

Cabaletta Bio stock forecast is as follows: an average price target of $16.33 (represents a 622.57% upside from CABA’s last price of $2.26) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

CABA Price Target

The average price target for Cabaletta Bio (CABA) is $16.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $3.00. This represents a potential 622.57% upside from CABA's last price of $2.26.

CABA Analyst Ratings

Buy

According to 7 Wall Street analysts, Cabaletta Bio's rating consensus is 'Buy'. The analyst rating breakdown for CABA stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cabaletta Bio Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 21, 2024Ben BurnettStifel Nicolaus$32.00$17.5482.44%1315.93%
Jan 03, 2023-Wells Fargo$14.00$9.3050.54%519.47%
Aug 30, 2022Michael UlzMorgan Stanley$3.00$1.25139.04%32.74%
Row per page
Go to

The latest Cabaletta Bio stock forecast, released on Mar 21, 2024 by Ben Burnett from Stifel Nicolaus, set a price target of $32.00, which represents a 82.44% increase from the stock price at the time of the forecast ($17.54), and a 1315.93% increase from CABA last price ($2.26).

Cabaletta Bio Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$32.00
Last Closing Price$2.26$2.26$2.26
Upside/Downside-100.00%-100.00%1315.93%

In the current month, the average price target of Cabaletta Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cabaletta Bio's last price of $2.26. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2024UBS-BuyInitialise
Sep 17, 2024H.C. WainwrightBuyBuyHold
Apr 29, 2024CitigroupBuyBuyHold
Apr 04, 2024CitigroupBuyBuyHold
Nov 15, 2023Cantor FitzgeraldOverweightOverweightHold
Jul 18, 2023Guggenheim-BuyInitialise
Jan 03, 2023Wells FargoOverweightOverweightHold
Sep 14, 2022Wells FargoOverweightOverweightHold
Aug 30, 2022Morgan Stanley-OverweightDowngrade
Row per page
Go to

Cabaletta Bio's last stock rating was published by UBS on Oct 10, 2024. The company Initialise its CABA rating from "null" to "Buy".

Cabaletta Bio Financial Forecast

Cabaletta Bio Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Cabaletta Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CABA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Cabaletta Bio EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict CABA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cabaletta Bio's previous annual EBITDA (undefined) of $NaN.

Cabaletta Bio Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-43.30M$-42.27M$-41.56M$-39.60M$-34.35M$-35.93M$-35.04M$-33.72M$-30.49M$-29.48M$-27.08M
High Forecast$-43.30M$-42.27M$-41.56M$-39.60M$-34.35M$-35.93M$-35.04M$-33.26M$-26.20M$-29.48M$-27.08M
Low Forecast$-43.30M$-42.27M$-41.56M$-39.60M$-34.35M$-35.93M$-35.04M$-34.18M$-33.35M$-29.48M$-27.08M
Surprise %-----------

Cabaletta Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CABA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cabaletta Bio SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Cabaletta Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CABA last annual SG&A of $NaN (undefined).

Cabaletta Bio EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.88$-0.85$-0.84$-0.80$-0.69$-0.73$-0.71$-0.68$-0.62$-0.60$-0.55
High Forecast$-0.88$-0.85$-0.84$-0.80$-0.69$-0.73$-0.71$-0.67$-0.53$-0.60$-0.55
Low Forecast$-0.88$-0.85$-0.84$-0.80$-0.69$-0.73$-0.71$-0.69$-0.67$-0.60$-0.55
Surprise %-----------

According to undefined Wall Street analysts, Cabaletta Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CABA previous annual EPS of $NaN (undefined).

Cabaletta Bio Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.51$6.001076.47%Buy
CABACabaletta Bio$2.26$16.33622.57%Buy
BDTXBlack Diamond Therapeutics$2.43$14.75507.00%Buy
LRMRLarimar Therapeutics$6.08$20.33234.38%Buy
PLRXPliant Therapeutics$12.73$39.71211.94%Buy
FIXXQ32 Bio$0.93$2.70190.32%Buy
DAWNDay One Biopharmaceuticals$13.62$38.80184.88%Buy
ETNB89bio$7.98$22.00175.69%Buy
STOKStoke Therapeutics$11.31$30.60170.56%Buy
ALECAlector$3.64$4.009.89%Buy
RVMDRevolution Medicines, Inc. Warrant$57.07$60.636.24%Buy
MDGLMadrigal Pharmaceuticals$317.09$315.75-0.42%Buy
ACLXArcellx$87.22$83.00-4.84%Buy

CABA Forecast FAQ

Is Cabaletta Bio a good buy?

Yes, according to 7 Wall Street analysts, Cabaletta Bio (CABA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of CABA's total ratings.

What is CABA's price target?

Cabaletta Bio (CABA) average price target is $16.33 with a range of $3 to $32, implying a 622.57% from its last price of $2.26. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cabaletta Bio stock go up soon?

According to Wall Street analysts' prediction for CABA stock, the company can go up by 622.57% (from the last price of $2.26 to the average price target of $16.33), up by 1315.93% based on the highest stock price target, and up by 32.74% based on the lowest stock price target.

Can Cabaletta Bio stock reach $3?

CABA's average twelve months analyst stock price target of $16.33 supports the claim that Cabaletta Bio can reach $3 in the near future.

What are Cabaletta Bio's analysts' financial forecasts?

Cabaletta Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-139M (high $-139M, low $-139M), average SG&A $0 (high $0, low $0), and average EPS is $-2.812 (high $-2.803, low $-2.821). CABA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-167M (high $-167M, low $-167M), average SG&A $0 (high $0, low $0), and average EPS is $-3.372 (high $-3.372, low $-3.372).